242 related articles for article (PubMed ID: 30908807)
1. Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.
Araki K; Fukuoka K; Higuchi H; Aizawa Y; Horikoshi Y
Pediatr Int; 2019 Jun; 61(6):572-577. PubMed ID: 30908807
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Doi A; Shimada T; Harada S; Iwata K; Kamiya T
Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
[TBL] [Abstract][Full Text] [Related]
3. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
4. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
5. Treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in children.
Katsuta T; Shoji K; Watanabe Y; Saitoh A
Pediatr Infect Dis J; 2013 Apr; 32(4):417-9. PubMed ID: 23274920
[TBL] [Abstract][Full Text] [Related]
6. Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.
Kim SH; Oh S; Huh K; Cho SY; Kang CI; Chung DR; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):937-944. PubMed ID: 30868326
[TBL] [Abstract][Full Text] [Related]
7. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
[TBL] [Abstract][Full Text] [Related]
9. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
[TBL] [Abstract][Full Text] [Related]
10. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
[TBL] [Abstract][Full Text] [Related]
11. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Asakura T; Ikeda M; Nakamura A; Kodera S
Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
[TBL] [Abstract][Full Text] [Related]
13. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
14. Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
Horie A; Nariai A; Katou F; Abe Y; Saito Y; Koike D; Hirade T; Ito T; Wakuri M; Fukuma A
Clin Exp Nephrol; 2019 Nov; 23(11):1306-1314. PubMed ID: 31428892
[TBL] [Abstract][Full Text] [Related]
15. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.
Matsumura Y; Yamamoto M; Nagao M; Tanaka M; Takakura S; Ichiyama S
Diagn Microbiol Infect Dis; 2016 Apr; 84(4):322-7. PubMed ID: 26782634
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
[TBL] [Abstract][Full Text] [Related]
18. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
19. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
20. High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.
Desta K; Woldeamanuel Y; Azazh A; Mohammod H; Desalegn D; Shimelis D; Gulilat D; Lamisso B; Makonnen E; Worku A; Mannerqvist K; Struwe J; Aspevall O; Aklillu E
PLoS One; 2016; 11(8):e0161685. PubMed ID: 27574974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
